Cytokine response to selected MTB antigens in Ghanaian TB patients, before and at 2 weeks of anti-TB therapy is characterized by high expression of IFN-γ and Granzyme B and inter- individual variation by Gloria Ivy Mensah et al.
RESEARCH ARTICLE Open Access
Cytokine response to selected MTB antigens in
Ghanaian TB patients, before and at 2 weeks of
anti-TB therapy is characterized by high expression
of IFN-γ and Granzyme B and inter- individual
variation
Gloria Ivy Mensah1,2*, Kennedy Kwasi Addo1, John Amissah Tetteh1, Sandra Sowah1, Thomas Loescher3,
Christof Geldmacher3,4 and Dolly Jackson-Sillah1
Abstract
Background: There has been a long held belief that patients with drug-susceptible TB are non-infectious after two
weeks of therapy. Recent microbiological and epidemiological evidence has challenged this dogma, however, the
nature of the Mtb-specific cellular immune response during this period has not been adequately investigated. This
knowledge could be exploited in the development of immunological biomarkers of early treatment response.
Methods: Cellular response to four Mtb infection phase-dependent antigens, ESAT-6/CFP-10 fusion protein and
three DosR encoded proteins (Rv1733c, Rv2029c, Rv2628) were evaluated in a Ghanaian TB cohort (n=20) before
and after 2 weeks of anti TB therapy. After 6-days in vitro stimulation, Peripheral blood mononuclear cell (PBMC)
culture supernatant was harvested and the concentration of IFN-γ, Granzyme B, IL-10, IL-17, sIL2Rα and TNF-α
were determined in a 6-plex Luminex assay. Frequencies of IFN-γ + CD4 and CD8 T cells were also determined in
an intracellular cytokine assay.
Results: All antigens induced higher levels of IFN-γ, followed by Granzyme B, TNF-α and IL-17 and low levels of
IL-10 and sIL-2R-α in PBMC before treatment and after 2 weeks of treatment. Median cytokine levels of IFN-γ,
Granzyme B, IL-17 and sIL-2R-α increased during week two, but it was significant for only Rv1733-specific production of
Granzyme B (P = 0. 013). The median frequency of antigen specific IFN-γ + CD4 T cells increased at week two; however,
only the increase in the ESAT-6/CFP-10-specific response was significant (P = 0. 0008). In contrast, the median frequency
of ESAT-6/CFP-10- specific IFN-γ + CD8 T cell responses declined during week two (P = 0. 0024). Additionally, wide
inter-individual variation with three distinct patterns were observed; increase in all cytokine levels, decrease in all
cytokine levels and fluctuating cytokine levels after 2 weeks of treatment.
Conclusion: The second week of effective chemotherapy was characterized by a general increase in cytokine
response to Mtb-specific antigens suggestive of an improvement in cellular response with therapy. However, the
wide inter-individual variation observed would limit the utility of cytokine biomarkers during this period.
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Background
Despite the availability since the 1980′s of an inexpen-
sive, efficacious, and moderately well-tolerated therapy,
that can cure 90% of cases, tuberculosis (TB) continues
to be a major worldwide health problem, with 8.6 mil-
lion new cases and 1.3 million deaths in 2012 [1]. One
of the factors mitigating against a decline in tuberculosis
cases is the long duration of treatment (6 months) which
makes adherence difficult and also puts pressure on
health care systems in developing countries [2]. Clinical,
bacteriological and radiological improvement in TB pa-
tients is achieved within 2 months upon effective
chemotherapy with a multi-drug regimen [3], making
“month 2 sputum culture status” the only acceptable
biomarker for TB treatment response [4]. However, wait-
ing for 2 months to reach a decision on the treatment
outcome could be damaging to a patient as it unduly de-
lays the need for drug sensitivity testing or changes in
treatment regimes. During this 2-month period, primary
multi-drug resistant organisms will remain untreated
and drug-resistant mycobacteria may have time to de-
velop resistance to additional drugs [5].
Additionally, use of classical microbiological methods
like “sputum culture status” as a biomarker for TB treat-
ment response has limited usefulness in children and
extra-pulmonary cases, where appropriate quality spu-
tum samples are hard to get. Given the shortcomings as-
sociated with using sputum as a sample for monitoring
TB treatment response, blood has been proposed as a
better alternative. Blood is easier to obtain and assess-
ment of immunological parameters in blood can be done
within days and could be well adapted for field use.
Measurement of Mtb-specific antigen induced responses
in peripheral blood has been used often in recent times,
however, most studies using this approach have only fo-
cused on IFN-γ as a sole marker of response. It has been
proposed that sets of markers rather than a single
marker may increase the predictive power [2]. Multiple
cytokines assessed at week two, a much earlier time
point during treatment than the current stipulated
“month two”, could be useful in detecting early cellular
response to TB treatment. There has been a long held
belief that patients with drug-susceptible TB are non-
infectious after two weeks of therapy [6,7] although re-
cent microbiological and epidemiological evidence has
challenged this dogma [8,7,9-11]. However, the nature of
the Mtb-specific immunological response during this
period of TB treatment has not been adequately investi-
gated. It has been demonstrated that Acid fast bacilli
(AFB) counts fall by about 20-fold in the first 2 days and
by a further 200-fold in the next 12 days to reduce the
counts of an initially smear-positive patient to about 103
per ml at 2 weeks of short course chemotherapy [12].
These levels are below the estimates of 103.5 to 104 per
ml which are the limits indicating a change from smear-
positive to smear-negative, culture-positive in untreated
patients [7]. If and whether this is characterized by an
improvement in cellular response can potentially be
exploited as a possible tool to predict early treatment re-
sponse. To address this knowledge gap, we identified, in
addition to IFN-γ, 5 key cytokines; Granzyme B (grzB),
TNF-α, IL-17, IL-10 and sIL-2R-α most of which are im-
portant to early control and containment of tuberculosis
infection.
Using the Luminex platform, we measured the levels
of the 6 selected host markers in the PBMC culture
supernatant of TB patients after 6 days long term stimu-
lation with ESAT-6/CFP-10 and 3 DosR antigens
(Rv1733c, Rv2029c, Rv2628) known to be immunogenic
in African populations [13] before and after 2 weeks of
treatment. A profile consisting of high levels (pg/ml) of
IFN-γ followed by Granzyme B and TNF-α and low
levels of IL-17, IL-10 and sIL-2R-α in PBMC before
treatment and at 2 weeks of treatment was observed.
We show that there is general improvement in cellular
response at 2 weeks of therapy but there is wide inter-
individual variation, suggesting that factors other than
anti TB therapy account for cellular response observed.
These ought to be investigated to further explore the po-




This study was approved by the Institutional Review
Board (IRB) of the Noguchi Memorial Institute for Medical
Research (NMIMR), University of Ghana, Legon, Accra.
Certified Protocol Number (CPN): 030/10-11). All partici-
pants were recruited upon written informed consent.
Study site and patients
A total of 20 newly diagnosed sputum smear-positive TB
patients who were yet to begin therapy, were recruited
consecutively from three health facilities in Accra, Ghana
during May to June 2011. The mean (±standard deviation
[SD] age was 34.05 (±9.25) years, and 80% were male. One
(1) HIV-positive participant was excluded from the ana-
lysis (Table 1). Patients were required to have at least one
of two sputum smears positive for acid -fast bacilli (AFB)
by direct microscopy to be eligible to take part in the
study. From each participant, up to 25 ml of venous blood
was drawn using butterfly needles (BD) into 10 ml hepa-
rinized vacutainers (BD). Blood samples were taken at two
time points; before treatment (baseline), and at 2 weeks of
TB treatment. All samples were sent immediately to the
laboratories of the Noguchi Memorial Institute for
Medical Research (NMIMR) for the appropriate analysis.
Demographic information was collected from each
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participant using a standardized questionnaire. Manage-
ment of TB cases followed the national guideline i.e. Two
months of intensive phase of Rifampicin (150 mg),
Isoniazid (75 mg), Pyrazinamide (400 mg) and Etham-
butol Hydrochloride (275 mg) and 4 months of the con-
tinuation phase with only Rifampicin and Isoniazid.
M. tuberculosis antigens
The recombinant M. tuberculosis proteins evaluated in
this study were; ESAT-6/CFP-10 fusion protein (a com-
bination of the two most immunodominant proteins of
the RD1 region of MTB) and Rv1733 (possible trans
membrane protein of 210 aa), Rv2029 (Phospho fructo
kinase B (pfkB) of 339aa), Rv2628 (Hypothetical protein
of 120aa) which are proteins of the Dormancy Survival
Regulon (DosR) of Mtb and which have been used previ-
ously and are known to be immunogenic in some African
populations [13]. These “stage specific” M. tuberculosis
antigens were selected and produced at the Department of
Infectious Diseases, Leiden University Medical Center,
Leiden, The Netherlands [14]. ESAT-6/CFP-10 was tested
on PBMC from all participants whilst Rv1733, Rv2029 and
Rv2628 were tested in 18, 11 and 10 participants respect-
ively. In all cases, 1 ug/ml of Staphylococcus enterotoxin B
(SEB) (Sigma: Cat. No. S4881) was included as a positive
control, while growth medium [(RPMI 1640 GIBCO, lot
no-3094131), 10% FBS (Fetal Bovine Serum (SIGMA:
catalog no. F9665), 1% Penicillin/Streptomycin (P/S)]
was used as a negative control. All Mtb antigens were
received in a dehydrated form and were reconstituted
with sterile growth medium and used at a final concen-
tration of 5 μg/ml. The working concentration of 5 μg/ml
was chosen based on a pilot study which showed that
while a concentration of 2.5 μg induced minimal secretion
of IFN-γ, there was no significant difference between the
secretion at 5 μg and 10 μg.
PBMC isolation
PBMC was isolated from heparinized whole blood fol-
lowing standardized procedures [15]. Briefly, using ster-
ile 10 ml disposable pipettes (Sarstedt), blood from the
three 10 ml vacutainers per participant was transferred
into a sterile 50 ml centrifuge tube (GBO) labeled with
the participant unique identification number. An equal
volume of pre-warmed (37°C) RPMI 1640 (GIBCO) was
added to the blood in the falcon tube to achieve a 1:1 di-
lution and mixed gently. The diluted blood was layered
gently onto 15 ml of Histopaque (SIGMA Lot No.
H8889) without breaching the Histopaque-blood barrier
in a ratio of 2:1 for blood and Histopaque. Both the
blood and Histopaque were used at room temperature.
The tubes were centrifuged at 800 g for 30 min at
room temperature with the brake off. The milky-white
ring of PBMC between the Histopaque (transparent)
and plasma (yellow) was then aspirated with a sterile
pastette into sterile 50 ml tubes, and washed twice
with pre-warmed Hank’s Balanced Salt Solution (SIGMA
Lot No. H9394). The cells were finally suspended in
1 ml of filtered growth medium for counting using 1
in 2 dilution with 0.4% Trypan blue (GIBCO: Cat.
No. 15250–061).
PBMC culture
Culture plates were prepared by adding 250 μl of antigen
suspension at 10 ug/ml to appropriate wells on the cul-
ture plates (Nunc; catalog no. 152640) in duplicates.
After counting, cells were re-suspended in pre-warmed
sterile filtered growth medium at 2million cells per ml
and aliquots of 250 μl (500,000 cells) added per well
of antigen and growth medium (negative control) to
achieve a final concentration of 5 μg/ml of antigen in
500 μl volume per well. Blank spaces were filled with
HBSS to prevent evaporation. The plate was covered
and sealed with Micropore tape and incubated for 6 days
at 37°C in a 5% CO2 incubator. The culture form was
then filled indicating the subjects IDs, start and end
Table 1 Participant’s characteristics
Participant Age group
(years)
Gender Sputum smear microscopy results
Diagnosis^ Category Month 2
01 41-50 M 3+ 3+ 3+ Neg
02 31-40 M 3+ 3+ 3+ Neg
03 51-50 M 2+ 2+ 2+ Neg
04 21-30 F 1+ Neg 1+ Neg
05 31-30 M 2+ 2+ 2+ Neg
06 21-30 M 3+ SC 3+ SC
07* 31-40 M 1+ 1+ 1+ Neg
08 51-60 M 3+ 3+ 3+ Neg
09 21-30 M 2+ 2+ 2+ Neg
10# 21-30 F 2+ 2+ 2+ Neg
11 31-40 M 3+ 3+ 3+ Neg
12 21-30 M 1+ 1+ 1+ Neg
13 31-40 F 3+ 3+ 3+ Neg
14 41-50 M 3+ 3+ 3+ Neg
15 31-40 M 3+ 3+ 3+ Neg
16 31-40 M SC SC SC Neg
17 31-40 M SC SC SC Neg
18 31-40 M 3+ 3+ 3+ Neg
19* 20-30 M SC Neg SC Neg
20 21-40 M SC Neg SC Neg
Average 34.05 M (80%) + (100%) (+) 5%
Range [21–55]
*M. africanum (MAF) #HIV + participant.
SC (Scanty) < 10 AFB per 100 fields ^Showing two smear results required for
TB diagnosis.
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date. The positive control antigen (SEB) was added
on the 4th day of culture. On the 5th day of culture,
the supernatant was collected and stored at −80°C for
further analysis and 5 μg/ml of Brefeldin A (Sigma:
Cat. No. B7651) was added to the cells for 18–24
hours until the 6th day when they were then pooled
into appropriately labeled FACs tubes (BD Falcon Cat
No: 352052) for intracellular cytokine staining and flow
cytometry.
Phenotypic analysis by intracellular flow cytometry
Each well was washed out gently with sterile FACS buf-
fer (1 X PBS, 1% HI-FCS, 0.1% NaN3) to completely
collect all cells. All tubes were placed on ice ensuring
cells are kept cold during staining. Two (2mls) of FACs
buffer was added per tube and centrifuged for 5 minutes
at 1250 rpm. The supernatant was decanted and the
pellet re-suspended in 100 μl FACS buffer and incu-
bated at 4°C in the dark for 30 mins wrapped in
aluminum foil with the appropriate amount of mono-
clonal antibody (Mab) for surface staining: 3 μl of
anti -CD4-peridinim chlorophyll (PerCP) (BD: Cat No.
345770); and 2 μl of anti- CD8-allophycocyanine (APC)
(BD: Cat no. 561421). After incubation, 2 ml of FACs
buffer was added per tube and centrifuged and dec-
anted as before. The cell pellet was then re-suspended
in 250 μl of BD Cytofix/Cytoperm (Cat. No. 554722) at
room temperature in the dark for 15 minutes to fix the
cells for intracellular staining. After fixing, cells were
permeabilized by washing 2 times with Iml of 1X BD
Perm/Wash buffer (Cat. No. 554723). For the second
wash, the cells were incubated with the perm wash for
25 minutes prior to centrifugation at 1800 rpm. The
supernatant was decanted, the pellet re-suspended in
the residual perm wash (approx. 50 μl) and 1 μl of
anti- IFN-γ-fluorescein isothiocyanate (FITC) (BD: Cat
No. 554551) added to the tubes and incubated for
30 minutes in the dark. After incubation, 2 ml perm
wash was added and centrifuged as before and the
supernatant decanted. The pellet was then re-suspended
in 0.3 ml of FACS flow solution and the cells were ac-
quired immediately on a FACS Calibur (BD). Using
FLOWJO software Version 7.6.2 (Tree Star Inc, USA), we
defined an R1 gate for lymphocytes in a dot plot of
Forward Scatter Chanel (FSC) versus Side Scatter Chanel
(SSC). To identify CD4+ and CD8+ T cells, events from
R1 were analyzed in a plot of CD4-PerCP vrs CD8-APC
(R2). Finally, gated CD4+ and CD8+ T cells were ana-
lyzed for IFNγ-FITC. Data were reported as percentages
of IFN-γ + CD4 and CD8 T cells. Compensation settings
were defined using anti-mouse kappa Comp Beads (BD
Biosciences) stained with each fluorochrome–conjugated
antibodies.
Human 6-PLEX (IFN-γ, TNF-α, IL-17, IL-10, sIL-2R-α and
Granzyme B) assay
Six-day culture supernatant previously harvested and
stored at −80°C were brought to room temperature to
thaw slowly until all ice had completely melted. Whilst
still ice cold, the samples were centrifuged to remove cell
debris after which an amount was dispensed into new
tubes and transported on ice for analysis. The multiplexing
analysis was performed using the Luminex™ 100 system
(Luminex, Austin, TX, USA) by Eve Technologies Corp.
(Calgary, Alberta- Canada). The six markers were mea-
sured in the cell culture supernatant using an Affymetrix
Human Cytokine/Chemokine Custom plex kit (Affymetrix,
Inc, Santa Clara, CA, USA) according to the manufac-
turer’s protocol. The 6-plex consisted of IFN-y, IL-10,
IL-17, IL-2Rα, Granzyme B, and TNF-α. The assay
sensitivities of the 6-plex markers ranged from 0.1 –
0.4 pg/ml, and 5 pg/ml for IL-2Rα and Granzyme B.
Determination of positive responses
For each antigen, values of S/U (where S/U is defined as
follows: cytokine concentration in antigen- stimulated
cultures divided by the cytokine concentration in un-
stimulated (negative control) as described in [16] that
were greater than or equal to 2 were considered positive
responses. In experiments where the concentrations of
cytokines in control cultures lacking antigens were not
detectable, the S/U values were determined by dividing
the concentration of a given cytokine in antigen-stimulated
cultures with the minimum detectable concentration of
the same cytokine.
Statistical analysis
Data was entered into Microsoft Excel 2007 (Microsoft
Corp., USA) for analysis or transported to Graph pad
PRISM version 4 (GraphPad prism software Inc., Califor-
nia, USA) for analysis and graphs. The minimum detect-
able concentrations of the cytokines or soluble mediator
in this assay were 5.7, 0.2, 0.26, 3.35, 1.39, 2.13 pg/ml for
Granzyme B, IFN-γ, IL-10, IL-17, sIL-2R-α and TNF-α
respectively. The Mann–Whitney U test was used to
compare the median concentration of each cytokine in
pg/ml at baseline and after 2 weeks of TB treatment and
to compare the cytokine secretion profile of antigens as-
sociated with the active (ESAT-6/CFP-10) and latency
(Rv1733) stages of TB infection. The Wilcoxon signed
rank text was used to compare cytokine expression at
baseline and 2 weeks of treatment for individuals (n = 9)
with samples for both time points available (Matched
analysis). The Wilcoxon rank sum test was used to com-
pare cytokine responses in single patients at baseline
and after 2 weeks of treatment. Uni-variate analysis was
done for “age” and “sputum smear result at diagnosis”
with cytokine response to antigenic stimulation to
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determine cause of individual variation in response ob-
served. In all cases P values less than 0. 05% were consid-
ered significant.
For flow cytometric analysis, percentage of IFN-γ +
cells were calculated by subtracting the percentage of
IFN-γ + cells in un-stimulated cultures from stimulated
ones. A threshold of 0.2% IFN-γ + CD4/ CD8 T cells de-
fined positive T-cell responses against antigens. Samples
with a negative SEB response were excluded from the
analysis. Differences in the percentage of IFN-γ + CD4/
CD8 T cells to antigenic stimulation were analyzed using
the nonparametric Mann–Whitney U-test. P–values of
less than 0.05 were regarded as significant.
Results
Participants’ characteristics
All twenty (20) participants were sputum smear positive,
however, they were categorized based on AFB smear
grading as 3+ (one or both smears were 3+), 2+ (one or
both smears were 2+ or lower), 1+ (one or both smears
were 1+ or lower) and SC (one or both smears was
scanty “less than 10 AFB per field” or negative). Accord-
ingly, nine (9) were classified as 3+, four (4) as 2+, three
(3) as 1+ and four (4) as SC (scanty). Eighteen (90%) of
the participants were infected with MTB and the
remaining two were infected with M. africanum (MAF).
All except one subject converted to a negative sputum
smear at 2 months of treatment (Table 1).
Antigen-induced secretion of cytokines by PBMC in
response to “stage specific” mycobacterial antigens
To ascertain the immunogenicity of each antigen in our
active pulmonary TB cohort, we compared the concen-
tration of cytokine (pg/ml) induction in the stimulated
to that of the un-stimulated culture. The cytokine con-
centrations were significantly higher (P < 0.05 to P < 0.001)
in stimulated than un-stimulated cultures for all antigens
tested at both baseline and after two weeks of therapy (data
not shown).
Positive responders and median cytokine concentration
Determining the proportion of positive responders to
M. tuberculosis antigens is critical to prioritizing the an-
tigens as there continues to be a search for the TB anti-
gen with universal immunogenicity. The positive control
SEB induced more positive responses than ESAT-6/CFP-
10 and the latency associated proteins Rv1733, Rv2029
and Rv2628 (Table 2). The role of IFN-γ during TB dis-
ease was evident as in response to all antigens, IFN-γ
levels were highest, followed by Granzyme B (Figure 1).
The same trend was observed at two weeks of treatment.
Generally median cytokine levels increased from baseline
to week 2 with only the increase in Rv1733-specific pro-
duction of Granzyme B (P = 0. 013) being significant.
Cytokine response to ESAT-6/CFP-10 fusion protein and
latency associated Rv1733
To determine whether differences exist in the cytokine
response profile to antigens associated with replicat-
ing (ESAT-6/CFP-10) and latent (Rv1733) bacilli, the
Wilcoxon matched pairs test was used to compare the
levels of each cytokine released in response to the two
antigens at baseline (T0) and 2 weeks (T1) of treatment.
This analysis included only patients (n = 9) with complete
data for all cytokines at both time points. There was no
difference (P > 0.05) in levels of the 6 cytokines induced
by ESAT-6/CFP-10 and the latency associated Rv1733 at
baseline (T0) and 2 weeks of treatment (T1). Median
concentration (pg/ml) of all cytokines (except TNF-α) in
response to ESAT-6/CFP-10 were higher at TI compared
to T0 and the same trend was observed with responses to
Rv1733. However, only the median increase of Rv1733-
specific Granzyme B response was of statistical signifi-
cance (P = 0. 01) (Figure 2).
Cytokine response to antigenic stimulation in individual
patients
To determine if the observed improvement in cellular re-
sponses was a reflection of individual cytokine responses
and not a group effect, analysis of cytokine responses to
ESAT-6/CFP-10 at baseline and 2 weeks of treatment
was done for individual patients (n = 12) who had both
data available. A wide inter-individual variation was ob-
served in cytokine response profile. As such, cytokine
responses to ESAT-6/CFP-10 were categorized based on
the three distinct response patterns observed from base-
line to week 2 as; (a) Increased median cytokine concen-
tration, (b) decreased median cytokine concentration and
(c) Fluctuations in median concentration for all 6 cyto-
kines (Figure 3). To understand this variation in cytokine
response pattern, a Uni-variate analysis was done for
“age” and “sputum smear result at diagnosis” with cytokine
response to antigenic stimulation (increased/decreased/
fluctuating) as outcome variables. However, no association
could be established.
Dynamics of MTB-specific CD4 and CD8 T cell responses
during the first two weeks of treatment
To determine the functional T cell phenotypes contrib-
uting to the cytokine secretion during the first two
weeks of treatment, we assessed the IFN-γ + CD4+ and
CD8+ T cells at baseline and at two weeks of treatment
in the same patients. After two weeks of treatment, the
median frequency of antigen specific IFN-γ + CD4 T cell
responses increased compared to baseline values; how-
ever, only the increase in the ESAT-6/CFP-10-specific
response was significant (P = 0. 0008). In contrast, the
median frequency of antigen specific IFN-γ + CD8 T cell
responses declined during week two, with the decline in
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ESAT-6/CFP-10 -specific (P = 0.0024) and Rv2029- specific
CD8 Tcell response (P < 0.009) being significant (Figure 4A
and B). The Wilcoxon matched pairs test analysis was done
on subjects for whom T cell responses at both time
points in response to ESAT-6/CFP-10 and Rv1733
(the strongest inducer of T cell responses among the
3 DosR proteins) were positive. Again the frequency
of IFN-γ + CD4 T cells in response to ESAT-6/CFP-10
was significantly increased (P = 0. 0078) at week two,
while the frequency of IFN-γ +CD8 T cells was signifi-
cantly decreased (P = 0. 0039) (Figure 4C). There were no
significant changes in response to Rv1733 (Figure 4D).
Discussion
Cytokine secretion profile in response to mycobacterial
antigens has been extensively studied in identifying im-
munological differences between active TB and latent
infection or in TB patients before and after treatment.
The first two weeks of TB treatment are known for the
rapid reduction of metabolically active mycobacteria, yet
studies on changes in the host immunological response
during this period are scanty. Such changes could be
exploited in the design of putative biomarkers for early
treatment response. Determining the cytokine secretion
profile of Mtb-specific antigens in different settings
would also expand our knowledge of the performance of
potential immunogenic M. tuberculosis antigens which
could be worthy candidates for designing new diagnostics
or vaccines [17]. In this study, the four tested MTB anti-
gens were immunogenic in our cohort as evidenced by
the highly significant differences (P < 0.01 to P < 0.0001)
seen between stimulated and un-stimulated cultures.
Consistent with other studies, [13,18,19] cytokine levels
in response to ESAT-6/CFP-10 fusion protein stimulation
Table 2 Positive cytokine responses per antigen before and after 2 weeks of TB treatment
No. of positive responders per antigen [n1/N2 (%)]
SEB E6/C10 Rv1733 Rv2029 Rv2628
Granzyme B
Before 19/19 (100) 13/19 (68.4) 13/18 (72.2) 7/11 (63.6) 7/10 (70)
After 2wks 14/15 (93.3) 12/15 (80.0) 9/10 (90.0) 7/7 (100.0) 5/5 (100)
P value 0.4412 0.6974 0.3746 0.1193 0.5055
IFN-γ
Before 18/19 (94.7) 16/19 (84.2) 15/18 (83.3) 8/11 (72.7) 8/10 (80.0)
After 2wks 12/15 (80.0) 13/15 (86.6) 10/10 (100) 7/7 (100) 5/5 (100)
P value 0.2994 1.0 0.5330 0.2451 0.5238
IL-10
Before 18/19 (94.7) 14/19 (73.7) 12/18 (66.7) 7/11 (63.6) 5/10 (50.0)
After 2wks 12/15 (80) 9/15 (60.0) 7/10 (70.0) 4/7 (57.1) 5/5 (100)
P value 0.2994 0.4748 1.0 1.0 0.1009
IL-17
Before 19/19 (100) 13/19 (68.4) 14/18 (77.8) 6/11 (54.5) 8/10 (80.0)
After 2wks 13/15 (86.6) 12/15 (80.0) 9/10 (90.0) 6/7 (85.7) 5/5 (100)
P value 0.1872 0.6974 0.6264 0.3156 0.5238
sIL-2R-α
Before 18/19 (94.7) 14/20 (70.0) 12/18 (66.7) 7/11 (63.6) 8/10 (80.0)
After 2wks 11/15 (73.3) 12/15 (80.0) 9/10 (90.0) 6/7 (85.6) 5/5 (100)
P value 0.1458 0.7003 0.3642 0.5956 0.5238
TNF-α
Before 16/19 (84.2) 13/19 (68.4) 12/18 (66.7) 7/11 (63.6) 7/10 (70.0)
After 2wks 11/15 (73.3) 9/10 (90.0) 9/10 (90.0) 5/7 (71.4) 5/5 (100)
P value 0.6722 0.3667 0.3642 1.0 0.5055
Positive cytokine responses per antigen at baseline and 2 weeks of anti-TB therapy. Freshly isolated PBMC from Sputum smear positive TB patients were stimulated for
6 days before initiation of therapy (baseline) with SEB (n = 19), ESAT-6/CFP-10 (n = 19), Rv1733 (n = 18), Rv2029 (n = 11) and Rv2628 (n = 10) and after 2 weeks on anti-TB
therapy with SEB (n = 15), ESAT-6/CFP-10 (n = 15), Rv1733 (n = 10), Rv2029 (n = 7) and Rv2628 (n = 5). Culture supernatant was assessed by multiplex cytokine analysis.
Percentage of positive cytokine (Granzyme B, IFN-γ, IL-10, IL-17, sIL2R-α and TNF-α) responses per antigenic stimulation were calculated. Positive responses were
determined as follows; Cytokine concentrations were divided by the negative control sample (medium only, un-stimulated) and values greater than or equal to 2 were
considered positive.
1Number of positive responses.
2Number of samples analyzed.
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were generally high. ESAT-6 is a virulence factor
secreted by actively replicating bacteria early during in-
fection, so high responses in TB patients at the early
stage of disease at are not unusual. However, cytokines
were secreted in response to the latency associated
antigens as well. The recognition of the latency-associated
antigens by PBMC from active TB patients could reflect
the fact that most TB patients undergo a latent infection
prior to TB disease [20] or indicate the simultaneous
involvement of latent and metabolically active bac-
teria in active disease. Thus an individual could harbour
actively replicating bacteria and succumb to TB, while
having latent foci that will lead to recognition of la-
tency related antigens. The immunodominance of Rv1733
across populations was affirmed as in agreement with
other studies, [13,18], Rv1733 was the most recognized (of
the 3 DosR antigens used) in our cohort in terms of posi-
tive cytokine responders and frequency of IFN-γ +T cell
response.
The cytokine profile in response to all antigenic stimu-
lation consisted of high levels of IFN-γ followed by grzB
and TNF-α and lower levels of IL-17, sIL2Rα and IL-10
Figure 1 High level of IFN-γ and Granzyme B are secreted in response to all antigens. Freshly isolated PBMC obtained from sputum smear
positive TB patients (n = 19) at baseline (before treatment) were stimulated in vitro with the stage specific M. tuberculosis antigens; ESAT-6/CFP-10,
Rv1733, Rv2029, Rv2628 (latency associated), positive control Staphylococcus enterotoxin B (SEB) and negative control (Growth medium) for 6 days.
The harvested supernatant were used in a six-plex Luminex assay for of Granzyme B (GrzB), IFN-γ, IL-10, IL-17, sIL2Rα and TNF-α. The box plots
show the 25th, 50th, and 75th percentiles, and the whiskers represent the minimum and maximum levels of cytokine (pg/ml) induced by each
stimulus. In response to all antigens, high levels of IFN-γ followed by Granzyme B and TNF-α and low levels of IL-17, sIL2Rα and IL-10
were observed.
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(Figure 1). It would be expected that ESAT-6/CFP-10
being virulent factors would induce both pro and anti
inflammatory cytokines whilst the dormancy -related
Rv1733, may only induce pro inflammatory responses
and relatively little anti-inflammatory response. This
actually confirms that the immune responses during
the active stage of the disease (TB patients) is charac-
terized by both pro and anti-inflammatory cytokines
irrespective of the nature of the antigen. While the
high IFN-γ levels were expected due to its critical role
in the control of Mtb infection, [21-23] the higher levels
of Granzyme B in this study in response to all antigens
was an interesting finding. In a previous study by Toosii
et al. [24] IFN-y and grzB were the only Mtb effector
molecules that were inducible in PBMC from Mtb-
sensitized subjects. In Mtb infections, the combined ac-
tion of perforin and the antibacterial agent granulysin,
both of which are expressed in the granules of CTLs and
NK cells, influences the outcome of infection [25]. Stud-
ies using mouse models indicate that the majority of
Mtb-specific CD8 + T cells are limited to either cyto-
toxicity or the secretion of IFN-γ, [26]. High levels of
grzB could indicate that the early stage of disease
control is characterized by lysis of infected cells to
quell the spread of infection and re-enforces the role
of CD8+ T cells in the control of human tuberculosis
infection. This was evident as we saw a higher fre-
quency of CD8+ T cells than CD4+ at baseline and a
decline in CD8+ T cells at week two and an increase
in IFN-γ + CD4 T cells. Marginal increases in cytokine
levels from baseline to week two as well as a signifi-
cant increase in the frequencies of CD4+ T cells was
observed, suggestive of an improvement in cellular re-
sponse with therapy. However, only the increase in
median Rv1733- specific Granzyme B secretion was of
statistical significance. Although effect of time point
and antigen on cytokine secretion could be observed
most of the trends were non-significant. It could be
because the sample size was too small to show any
differences or cytokines assessed remain relatively un-
changed or stable from baseline to week two of treat-
ment. Improvement in cellular response with therapy
has been reported in previous studies [27-30].
Two reasons have been adduced for this cellular im-
provement, firstly an increase in the number of periph-
eral CD4+ T cells that produce IFN-γ, owing to the fact
Figure 2 ESAT-6/CFP-10 fusion protein and latency associated Rv1733 induce comparable levels of the 6 cytokines. Cytokine levels
induced by ESAT-6/CFP-10 (EC) fusion protein and Latency associated Rv1733 at baseline (T0) and 2 weeks (T1) of treatment were compared
using the Wilcoxon matched pairs test in patients who had data for both time points available (n = 9). Cytokine levels were obtained after
subtracting values in un-stimulated wells from stimulated wells and negative values were converted to zero. The box plots show the 25th, 50th,
and 75th percentiles, and the whiskers represent the minimum and maximum levels of cytokine (pg/ml) induced by each stimulus. For each
cytokine, the comparison was done between the amount secreted by ESAT-6/CFP-10 vrs Rv1733 at baseline (T0) and that between ESAT-6/
CFP-10 vrs Rv1733 at week two (T1). P values of <0.05 were considered significant.
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that CD4+ T cells responsive to a vast array of Mtb epi-
topes are sequestered or compartmentalized at the site
of the disease, and appear in the peripheral blood after
effective chemotherapy, which reverses the state of anergy
seen in these patients [27,30]. This is actually corroborated
by our study as the median frequency of IFN-γ +CD4
T cells increased during week 2 from baseline levels.
Secondly a shift in cytokine production by PBMC from
cytokines that down regulates the activation of Th1 cells
and their cytokines such as IL-10. The levels of these regu-
latory cytokines are high in active TB patients and de-
crease upon treatment with anti-TB drugs [31,32].
In-spite of this general improvement in cytokine re-
sponses, inter-individual variation was observed with 3
distinct patterns of Increased, decreased or fluctuating
levels of all cytokines. We could not detect an association
between “age” and “sputum smear result at diagnosis” with
cytokine response to antigenic stimulation. The variation
Figure 3 Changes in cytokine levels after 2 weeks of TB treatment follows three patterns. Cytokine levels at baseline and after two weeks
of treatment in response to each antigen were determined for each patient. Cytokine levels were calculated by subtracting the background
(value of un-stimulated control) from measured values for each cytokine. Data was analyzed using Wilcoxon signed rank test and P values <0.05
were considered significant. Shown are the cytokine profiles of patients (n = 12) who had both time points available for response to ESAT-6/CFP-10. In
patients A1, L2, M10, M9 there is a significant decrease in all cytokine levels at week two, while in patients A6, M4, M2, M6, M5 there is a significant
increase in all cytokine levels. The increase and decrease in cytokine levels in A5 and L1 respectively, are not significant while M1 shows
fluctuating levels.
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could be best explained by host intrinsic factors beyond
the scope of this study.
This study had some limitations, including the small
sample size (n = 20), and limited number of analytes tested
for (6 cytokines). Also, we could not take sputum samples
at week 2 which would have permitted us to directly com-
pare the changes in the cytokine profile to smear status
(bacterial load) at week 2 and perhaps would have helped
to better explain the individual variation in response. Also,
epidemiological factors were not considered.
Conclusion
In conclusion, effective chemotherapy improved cellular
responses of TB patients to Mtb stage specific antigens,
as early as two weeks of anti-TB therapy, characterized
by a general increase in secretion of various cytokines.
However, using cytokine levels to predict early treatment
response to anti-TB treatment will be difficult due to
the wide inter-individual variation observed. While the
amount of cytokines produced may not be an indication of
its biological activities, the high quantities of Granzyme B
warrants further investigation of its role in the control of
TB infection and the possible utility as a marker for early
TB treatment response.
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ESAT-6/CFP-10, Rv1733, Rv2029, Rv2628, SEB and the un-stimulated control (Medium). IFN-γ + CD4+ and IFN-γ + CD8+ T cells were assessed
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cells defined positive T-cell responses against antigens. The Mann–Whitney U test (P < 0.05) was used to compare frequency of IFN-γ + CD4
(A) and CD8 (B) T cells at baseline and week two in response to ESAT-6/CFP-10 (n = 11), Rv1733 (n = 10), Rv2029 (n = 6), Rv2628 (n = 6). Also
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